Tim Hirst is based in Canberra, Australia and is an experienced angel investor, entrepreneur and company director with a particularly interest in the medtech, biotech and pharmaceuticals sectors. He a member of a number angel investment groups in Australia (in Adelaide, Canberra and Sydney) and the US (New York and Palo Alto) in which he specialises in undertaking extensive scientific due diligence. During his earlier academic career he was an internationally acknowledged molecular microbiologist working on bacterial toxins, immune modulation and vaccine development, publishing over 150 research articles, reviews and book chapters. He was Professor and Head of Microbiology at the University of Bristol UK and Vice-President & Deputy Vice-Chancellor at the University of Sydney, before moving into the venture capital industry as CEO of ANU Connect Ventures – a $30M pre-seed investment fund. He is currently the Executive Chairman of Gamma Vaccines Pty Ltd – a company developing improved vaccines for influenza and pneumococcal disease and Chairman of OzStar Therapeutics Pty Ltd – a company focussed on an adjunctive treatment for type 2 diabetes. He is also an Honorary Professor in the School of Biological Sciences at the University of Adelaide, Australia.